AOD-9604

The speaker acknowledges that AOD-9604 failed in formal clinical trials for weight loss. This is presented as context for why most users report seeing no results when using the peptide in isolation. No specific trial names, dates, or outcome data are cited.

The speaker identifies low circulating insulin as the key physiological condition that allows AOD-9604-driven fat mobilization to result in actual fat oxidation. By implication, injecting in a fed or hyperinsulinemic state would blunt the peptide's utility. This is presented as mechanistic reasoning without citation of specific studies.

The speaker provides a specific timing recommendation: inject AOD-9604 during a fasting window when circulating insulin levels are low. The rationale is that low insulin is a prerequisite for fat mobilization to translate into actual fat oxidation. No specific injection dose, volume, or frequency is mentioned.

Therapeutic or intermittent fasting is presented as a second strategy to pair with AOD-9604, creating the low-insulin, energy-deficit environment needed for mobilized fat to be oxidized rather than re-stored. No specific fasting protocols (e.g., 16:8, 24-hour) or durations are specified.

The speaker recommends stacking AOD-9604 with GLP-1 receptor agonist medications (e.g., semaglutide, tirzepatide — though specific agents are not named) as one strategy to create the caloric deficit needed to convert fat mobilization into net fat loss. No dosages, ratios, or safety considerations for this combination are discussed.

The speaker's core protocol recommendation is that AOD-9604 must be combined with a caloric deficit to produce meaningful fat loss results. Without an energy deficit, mobilized fatty acids are reportedly re-esterified and stored back in adipose tissue. No specific caloric targets or deficit magnitudes are provided.

The speaker explicitly states that AOD-9604 does not suppress appetite and does not boost metabolic rate. Its sole claimed utility is increasing the availability of mobilized fat for use as fuel. This distinguishes it mechanistically from GLP-1 receptor agonists and other weight-loss agents.

The speaker describes AOD-9604's primary mechanism as fat mobilization — releasing stored fat into the bloodstream — rather than directly oxidizing or burning fat. The analogy used is 'opening a vault of cash': the fat is freed from storage but must be actively utilized or it will be re-deposited. No dosage information is provided.

The speaker explicitly states that stacking fat-loss peptides with GLP-1 agonists should be done 'under medical supervision.' This is the only safety caveat offered in the video. No specific contraindications, side effects, or patient screening criteria are discussed.

The speaker recommends stacking one or two fat-loss peptides (AOD-9604, MOTS-c, and/or 'loop 332') alongside GLP-1 medications to address multiple metabolic systems simultaneously and break weight-loss plateaus. No specific stacking protocols, dosages, timing, or cycling guidance is provided. This is presented as a general clinical framework, not backed by cited trials.

AOD-9604 is described as a fragment of growth hormone that specifically targets stubborn fat mobilization. The speaker claims it unlocks fat stores without impacting appetite or blood sugar levels, making it complementary to GLP-1 therapy. No dosages or study citations are provided.

When asked whether to introduce new peptides after lowering a GLP-1 dose, Dr. Jones states he would be introducing peptides throughout the entire program — starting from the beginning with fat-mobilizing peptides like AOD-9604, rather than waiting until later stages.

When asked whether AOD-9604 and cagrilintide can be combined, Dr. Jones confirms it is possible but expresses a preference for other GLP-1 options over cagrilintide ('Kaggy'). He frames this as theoretically acceptable but not his first-choice protocol.

Dr. Jones recommends introducing a fat-mobilizing peptide like AOD-9604 at the beginning of a GLP-1 program. He categorizes AOD as a 'fat mobilizing peptide' and suggests stacking it with GLP-1 medications from the start of treatment rather than waiting until later.